DOI: 10.1038/s41467-022-33244-6; PMCID: PMC9485122
Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor outcomes and relapse risk prediction approaches have not changed significantly in decades. To build a robust transcriptional risk prediction model for pediatric AML, we perform RNA-sequencing on 1503 primary diagnostic samples. While a 17 gene leukemia stem cell signature (LSC17) is predictive in our aggregated pediatric study population, LSC17 is no longer predictive within established cytogenetic and molecular (cytomolecular) risk groups. Therefore, we identify distinct LSC signatures on the basis of AML cytomolecular subtypes (LSC47) that were more predictive than LSC17. Based on these findings, we build a robust relapse prediction model within a training cohort and then validate it within independent cohorts. Here, we show that LSC47 increases the predictive power of conventional risk stratification and that applying biomarkers in a manner that is informed by cytomolecular profiling outperforms a uniform biomarker approach.
Biomarkers; Child; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; RNA; Recurrence
Biomarkers; Gene Expression Profiling; Acute Myeloid Leukemia; Neoplastic Stem Cells; RNA; Recurrence
Huang BJ, Smith JL, Farrar JE, et al. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nat Commun. 2022;13(1):5487. Published 2022 Sep 19. doi:10.1038/s41467-022-33244-6